The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C

İdilman, Ramazan; Maria, Nicola De; Colantoni, Alessandra; Nadir, Abdul; Thiel, David H. Van

doi:10.1111/j.1572-0241.2002.05482.x

Cited by 53 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 23 full-text articles that were evaluated, 11 articles fulfilled the selection criteria and were included in the systematic review. [13][14][15][16][18][19][20][21][22][23][24] These 11 studies resulted in 14 datasets because one study each reported data for non-cirrhotic and cirrhotic patients, 15,21 and one study used different vaccination schedules. 22 These three studies were managed as separate reports.…”

Section: Discussionmentioning

confidence: 99%

Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: A systematic review and meta‐analysis

Liu

Chen

2017

Hepatology Research

View full text Add to dashboard Cite

Hepatitis B virus and hepatitis C virus (HCV) co-infection can add to the severity of hepatitis and the risks of liver cirrhosis and hepatocellular carcinoma. Whether chronic HCV infection decreases antibody response to hepatitis B vaccination is still controversial. We evaluate the influence of HCV infection on antibody response to hepatitis B vaccination by a systematic review of published works with a meta-analysis of clinical trials. The random-effects model of DerSimonian and Laird with heterogeneity and sensitivity analyses were used in this study. The end-point of interest was the rate of patients showing seroconversion of antibody responses at completion of hepatitis B vaccination schedule among patients with chronic HCV infection versus healthy controls. We identified 11 studies involving 704 patients with HCV and 812 controls. Our results show a significant decrease in antibody seroconversion rates among patients with HCV versus healthy controls (pooled odds ratio = 0.17 [95% confidence interval, 0.11-0.28]). The P-value was 0.21 for our test of study heterogeneity. Stratified analysis in subgroups of interest and sensitivity analysis did not meaningfully change our results. Our meta-analysis showed patients with hepatitis C infection have a statistically significant lower rate of seroconversion in comparison to healthy controls, both in cirrhotic and non-cirrhotic patients. Chronic HCV infection can decrease the immune response to a standard schedule of hepatitis B vaccination. Further studies are needed to investigate the optimum vaccination schedule for patients with chronic HCV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: A systematic review and meta‐analysis

Liu

Chen

2017

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…In contrast, De Maria et al (20) and Idilman et al (21), in a study of 152 chronic HCV patients and 26 controls vaccinated with high-dose vaccine (40 μg recombinant HBsAg) at accelerated intervals (zero, one and two months), found a difference in response in patients with chronic hepatitis with and without histologically verified cirrhosis. A significant difference in vaccine response rate was found when all HCV-positive patients were compared with controls (72% versus 92%, respectively).…”

Section: Hbv Vaccinationmentioning

confidence: 94%

Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations

Buxton

Kim

2007

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in patients with chronic liver disease. The present article reviews HAV and HBV vaccine responses reported in the literature when administered to individuals with chronic HCV infection, and reviews current national and international recommendations.RESULTS: Persons with chronic HCV respond well to HAV vaccine, but studies exploring HBV vaccine efficacy in this population have equivocal results. Vaccine schedules and participant characteristics differ among studies, and most do not adjust for confounders. Some studies found no difference in HBV vaccine response between patients with chronic HCV and controls. However, HBV vaccine response was generally reduced in those with cirrhosis and HCV genotype 1. Organizations recommend HAV and HBV vaccines for persons with chronic HCV, but do not suggest alterations in schedule or dose.RECOMMENDATIONS: Because HAV vaccine response is good and routine laboratory testing may not detect lower levels of vaccine-induced anti-HAV, the standard HAV vaccine schedule is recommended without postimmunization testing. HBV vaccine should be administered early in the course of chronic HCV infection because response may be lower in patients with cirrhosis. Reflex testing of anti-HCV reactive sera for anti-HAV and hepatitis B surface antibody can facilitate appropriate follow-up and timely immunization. Determination of postimmunization hepatitis B surface antibody, especially in patients with cirrhosis or genotype 1, will allow HBV vaccine boosters to be offered.

show abstract

“…But Idilman et al [20] found the difference in vaccine response was restricted to the cirrhotic patients (54% HBV vaccine response vs 72% in non-cirrhotic chronic HCV patients).…”

Section: Discussionmentioning

confidence: 98%

Efficacy of Hepatitis B Virus Vaccination and Antibody Response to Reactivation Dose Among Adult Non-Responders to Primary Hepatitis B Vaccination in Chronic Hepatitis C Egyptian Patients

Al-zahaby

Zaky

Hussien

et al. 2017

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

and often fulminant course of the disease. Additionally, HCV patients may be at a higher than an average risk of acquiring hepatitis B because of the similar routes of transmission of both viruses. HBV infection can be prevented by the administration of a safe and immunogenic vaccine. Insufficient immune response to hepatitis B virus (HBV) vaccine in patients with chronic hepatitis C virus is frequently encountered and anti-HBs levels may persist for a shorter time than among immune competent persons. The purpose of present study was to determine long-term persistence of anti-HBs among Egyptian patients with chronic hepatitis C infection. It also assesses the need and response to a subsequent challenge with vaccine booster doses. METHODS: 200 individuals were enrolled; (GI) 100 patients suffered from chronic HCV infection and 100 healthy individuals as a control (GII). Both groups were matched in regard to age and sex. Each individual received a standard 3-dose series of HBV vaccine; 20µg recombinant DNA vaccine of HBV(Euvax-B LG Life science, Korea) administered by IM injection into deltoid muscle at 0, 1, 6 months interval. HBs antibody titer was measured after 4 weeks. Suboptimal or Non-responders (anti-HBs titer < 10 IU/L) received a booster dose and reevaluated after 4 weeks; Suboptimal response of group I (42 patients) divided into 2 subgroups: GIa (21 patients), which received 40 µg(double dose) recombinant HBV vaccine and GIb (21 patients), received standard adult dose 20 µg HBV vaccine. 11 individuals with suboptimal response of G II received standard adult dose 20 µg HBV vaccine too. CONCLUSION: Chronic HCV patients showed lower response rate for standard doses of HBV vaccine especially with advancing age, diabetes and hypoalbuminemia. A double booster dose (40 μg) vaccine would be recommended for them which are better than revaccination with the standard 3 doses recombinant HBV vaccine.

show abstract

The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C

Abstract: A high dose, short interval HBV vaccination schedule is safe in individuals with chronic hepatitis C. From these data, it is suggested that a high dose and a short interval between HBV vaccinations may produce an effective and early antibody response in such patients.

Cited by 53 publications

References 24 publications

Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: A systematic review and meta‐analysis

Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: A systematic review and meta‐analysis

Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations

Efficacy of Hepatitis B Virus Vaccination and Antibody Response to Reactivation Dose Among Adult Non-Responders to Primary Hepatitis B Vaccination in Chronic Hepatitis C Egyptian Patients

Contact Info

Product

Resources

About